
Max Marchione, founder and CEO of SuperPower, joins Jonathan Stern to discuss the longevity market, Hims' recent Super Bowl ad, and the future of health super apps. Marchione analyzes Hims' marketing strategy of targeting middle America by "punching at rich people" and identifies three potential future strategies for Hims: membership platform, manufacturing, and biotech. He also shares his thoughts on the peptide market, predicting that the majority of Americans will have tried an injectable peptide within three years, with GLP-1s remaining the most popular. Marchione highlights Retatrutide as the best-selling gray market peptide and explains SuperPower's strategy of building great technology and a platform to replace primary care.
Sign in to continue reading, translating and more.
Continue